Type : | Industriel |
Statut : | Ouvert |
Phase : | III |
Étape du traitement : | Traitements combinés |
Date d'ouverture : | 13/01/2021 |
Date clôture : | 30/10/2024 |
Promoteur : | Gilead Sciences |
Progression du cancer: | Loco-régional |
The primary objective of this study is to assess overall survival (OS) with sacituzumab govitecan-hziy in comparison with treatment of physician's choice (TPC) in participants with metastatic or locally advanced unresectable urothelial cancer (UC).
- Cancers uro-génitaux
- Vessie
- Tumeur maligne de la vessie - Cim10 : C67